Pacritinib in CMML
NCT06159491
Recruiting
This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated with a hypomethylating agent (HMA) must have received ≤ 1 cycle. Pacritinib will be initially tested at a dose of 200mg twice daily (dose level 0) in combination with azacitidine 75mg/m2, which can be administered subcutane... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: The Mount Sinai Hospital, New York, New York
Conditions: Chronic Myelomonocytic Leukemia
Register for Updates
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211
Recruiting
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
08/15/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +39 locations
Conditions: Single Ventricle Heart Disease
Register for Updates
A New Intervention to Improve Function in Veterans With Anxiety and Depression
NCT06188923
Recruiting
Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain. Since all these symptoms frequently occur together, they may have a common underlying biological basis. A single medication that could effectively treat all these symptoms would b... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/15/2025
Locations: Durham VA Medical Center, Durham, NC, Durham, North Carolina
Conditions: Anxiety and Depression
Register for Updates
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274
Recruiting
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +27 locations
Conditions: Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor, Metastatic Midgut Neuroendocrine Tumor G1, Metastatic Midgut Neuroendocrine Tumor G2
Register for Updates
Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension
NCT06554340
Recruiting
The goal of this study is to determine if 12 weeks of cycling exercise training at home will improve three parameters: 1) blood pressure, 2) cognition, and 3) walking ability among persons with multiple sclerosis who have high blood pressure, when compared to a group that engages in a 12-week home-based stretching program. The main questions this study aims to answer are: 1. Can home-based cycling exercise training improve blood pressure by increasing blood vessel dilation in people with multi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: UMass Boston, Boston, Massachusetts
Conditions: Multiple Sclerosis, Hypertension
Register for Updates
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
NCT06071624
Recruiting
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida 33136, Miami, Florida +1 locations
Conditions: Chronic Myelomonocytic Leukemia
Register for Updates
Trial of a Culturally Informed Brief Intervention to Reduce Alcohol Related Health Disparities and Treatment Inequities Among Latinxs
NCT05800899
Recruiting
This Stage II Randomized Efficacy Trial will compare the effectiveness of a theoretically informed and culturally responsive brief motivational intervention to a non-adapted brief intervention among non-treatment seeking Latinxs admitted for medical treatment of an injury who engage in at risk drinking or were drinking at the time of their injury. The culturally informed brief motivational intervention (CI-BMI) increases autonomous motivation to engage in protective drinking behavior and reduce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: University Medical Center of El Paso, El Paso, Texas
Conditions: Alcohol Use Disorder
Register for Updates
PAS-004 in Patients With Advanced Solid Tumors
NCT06299839
Recruiting
The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate different doses of PAS-004, and * What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: NEXT Oncology, Austin, Texas +6 locations
Conditions: RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Register for Updates
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: HonorHealth, Scottsdale, Arizona +75 locations
Conditions: Hypertension, Hypertension, Systolic, Hypertension, Essential
Register for Updates
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
NCT06390956
Recruiting
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
Conditions: Marginal Zone Lymphoma
Register for Updates
LH Canine Therapy Study
NCT05840198
Recruiting
The goal of this pilot project is to test for initial efficacy of the Recovery \& Care Canine-Assisted Therapy program that has been developed and implemented in youth institutionalized for behavioral and emotional problems. We are using two study sites, Lawrence Hall and Lydia Home, both Chicago-based residential treatment centers for youth with behavioral and emotional problems, many of whom have experienced child maltreatment and trauma. Comparisons will be made to a matched sample of youth f... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
08/15/2025
Locations: Lawrence Hall Child & Family Treatment Center, Chicago, Illinois +1 locations
Conditions: Emotion Regulation, Behavioral Disorder, Self Esteem
Register for Updates
Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
NCT05992311
Recruiting
The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
08/15/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, Texas
Conditions: Gulf War Syndrome
Register for Updates